Comparison of Two Manufacturing Processes of Daprodustat for Bioequivalence and Dissolution in Healthy Volunteers: A Randomized Crossover Study.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical pharmacology in drug development"
DOI: 10.1002/cpdd.1257
Abstract: Daprodustat, an orally bioavailable hypoxia-inducible factor-prolyl hydroxylase enzyme inhibitor, has recently completed phase 3 clinical development for treating anemia of chronic kidney disease. Part A of this 2-part, randomized, double-blind, single-dose, cross-over study (NCT04640311) compared… read more here.
Keywords: tablets manufactured; dissolution; bioequivalence; manufacturing processes ... See more keywords